Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Celyad enter into license agreement with Medisun for C-Cure in Greater China By PBR Staff Writer
Belgian biopharmaceutical firm Celyad has entered into a new collaboration and distribution agreement with its Hong-Kong based partner, Medisun International Limited (Medisun) for C-Cure, its lead cardiac disease cell therapy candidate.
Contract Research & Services > Contract Services > News
Recipharm to manufacture RedHill's RHB-105 to treat H. pylori infection By PBR Staff Writer
Swedish contract development and manufacturing organization (CDMO) Recipharm has signed an agreement with Israeli biopharmaceutical firm RedHill Biopharma to manufacture its late-stage patented drug candidate, RHB-105 to treat Helicobacter pylori (H. pylori) bacterial infection.
Contract Research & Services > Contract Services > News Takeda to expand rights related to Nanotherapeutics’ Vero cell technology platform By PBR Staff Writer
Takeda Pharmaceutical has entered into an agreement to acquire expanded commercialization and technology access rights related to Nanotherapeutics’ Vero cell technology platform, a cell culture-based platform for vaccine production.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Medivation to acquire worldwide rights of BioMarin's cancer drug talazoparib
By PBR Staff Writer
US-based biopharmaceutical firm Medivation has agreed to acquire all worldwide rights of BioMarin Pharmaceutical's talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor.
Contract Research & Services > Contract Services > News
STA to market and distribute PharmaMar's cancer drug Aplidin in Australia and New Zealand
By PBR Staff Writer
PharmaMar has entered into an exclusive license and commercialization agreement with the Australian pharmaceutical firm Specialised Therapeutics Australia (STA) to market and distribute the cancer drug candidate Aplidin (plitidepsin) in Australia and New Zealand.
Contract Research & Services > Contract Services > News
Amgen partners with academia to support Cancer Patient Advocacy Organizations
By PBR Staff Writer
Amgen has entered into a multi-year partnership with Center for Social Sector Leadership at the University of California (UC), Berkeley's Haas School of Business to introduce a graduate-level course on gauging outcomes of cancer patient advocacy education and support programs.
Contract Research & Services > Contract Services > News
R-PHARM acquires IXEMPRA from Bristol-Myers, launches US commercial operations
R-PHARM US announces the acquisition of IXEMPRA (ixabepilone) from Bristol-Myers Squibb (BMY). IXEMPRA received marketing approval from the US Food and Drug Administration in 2007 and in 18 other markets globally.
Contract Research & Services > Contract Services > News
SIFI to distribute Alimera's DME treatment Iluvien in Italy, San Marino and Vatican City
By PBR Staff Writer
US-based Alimera Sciences' European subsidiary Alimera Sciences Limited has signed an exclusive five-year agreement with Societa Industria Farmaceutica Italiana (SIFI) for distribution of Iluvien in Italy, San Marino and Vatican City.
Contract Research & Services > Contract Services > News
Janssen to develop and commercialize Alligator's immuno-oncology agent ADC-1013
By PBR Staff Writer
Janssen Biotech has entered into an exclusive, worldwide license agreement with Swedish biotech firm Alligator Bioscience for ADC-1013, an immuno-oncology agent currently being evaluated in Phase I clinical trials.
Contract Research & Services > Contract Services > News
Sanofi, Evotec and Apeiron to develop new small molecule immuno-oncology treatments
Sanofi announced that it has entered a research collaboration and license agreement with Evotec and Apeiron Biologics to discover and develop first-in-class small molecule-based immuno-oncology therapies to treat solid and hematological cancers by enhancing the anti-tumor activity of the human immune system.
Contract Research & Services > Contract Services > News
DKSH signs agreement with Actelion to drive growth in Asia
By PBR Staff Writer
DKSH Business Unit Healthcare and Actelion's affiliate Actelion Pharmaceuticals Singapore have entered into collaboration to support the business growth in Asia.
Contract Research & Services > Contract Services > News
Gliknik licensee Pfizer gets FDA orphan drug status for GL-2045 to treat rare neurological disorder
By PBR Staff Writer
Gliknik has announced that its licensee Pfizer has received orphan drug designation from the US Food and Drug Administration (FDA) for its autoimmune candidate drug GL-2045 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests